These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1036 related articles for article (PubMed ID: 29976679)

  • 21. Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models.
    Shukla R; Beesetti H; Brown JA; Ahuja R; Ramasamy V; Shanmugam RK; Poddar A; Batra G; Krammer F; Lim JK; Kale S; Lal AA; Swaminathan S; Khanna N
    EBioMedicine; 2020 Oct; 60():102991. PubMed ID: 32949997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
    Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancement.
    Hughes HR; Crill WD; Chang GJ
    Virol J; 2012 Jun; 9():115. PubMed ID: 22709350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts.
    Priyamvada L; Cho A; Onlamoon N; Zheng NY; Huang M; Kovalenkov Y; Chokephaibulkit K; Angkasekwinai N; Pattanapanyasat K; Ahmed R; Wilson PC; Wrammert J
    J Virol; 2016 Jun; 90(12):5574-85. PubMed ID: 27030262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones.
    Smith SA; de Alwis AR; Kose N; Jadi RS; de Silva AM; Crowe JE
    J Virol; 2014 Nov; 88(21):12233-41. PubMed ID: 25100837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera.
    Wahala WM; Huang C; Butrapet S; White LJ; de Silva AM
    J Virol; 2012 Apr; 86(7):4019-23. PubMed ID: 22278250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Mapping of the B Cell Neutralizing Epitopes on ED III of Envelope Protein from Dengue Virus].
    Lin Y; Wen K; Guo Y; Qiu L; Pan Y; Yu L; Di B; Chen Y
    Bing Du Xue Bao; 2015 Nov; 31(6):665-73. PubMed ID: 26951013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dengue virus envelope protein domain III-elicited antibodies mediate cross-protection against Zika virus in a mouse model.
    Zhou Y; Chen D; Yang L; Zou W; Duan Z; Zhang Y; Wen J
    Virus Res; 2020 Mar; 278():197882. PubMed ID: 31981774
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes.
    Gallichotte EN; Baric TJ; Yount BL; Widman DG; Durbin A; Whitehead S; Baric RS; de Silva AM
    PLoS Pathog; 2018 Feb; 14(2):e1006934. PubMed ID: 29481552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Generation of Monoclonal Antibodies against Dengue Virus Type 4 and Identification of Enhancing Epitopes on Envelope Protein.
    Tang CT; Liao MY; Chiu CY; Shen WF; Chiu CY; Cheng PC; Chang GJ; Wu HC
    PLoS One; 2015; 10(8):e0136328. PubMed ID: 26309127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera.
    de Alwis R; Williams KL; Schmid MA; Lai CY; Patel B; Smith SA; Crowe JE; Wang WK; Harris E; de Silva AM
    PLoS Pathog; 2014 Oct; 10(10):e1004386. PubMed ID: 25275316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.
    VanBlargan LA; Mukherjee S; Dowd KA; Durbin AP; Whitehead SS; Pierson TC
    PLoS Pathog; 2013; 9(12):e1003761. PubMed ID: 24348242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection.
    Ramadhany R; Hirai I; Sasaki T; Ono K; Ramasoota P; Ikuta K; Kurosu T
    Antiviral Res; 2015 Dec; 124():61-8. PubMed ID: 26522769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection.
    Tsai WY; Lai CY; Wu YC; Lin HE; Edwards C; Jumnainsong A; Kliks S; Halstead S; Mongkolsapaya J; Screaton GR; Wang WK
    J Virol; 2013 Dec; 87(23):12562-75. PubMed ID: 24027331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural and Functional Characterization of a Cross-Reactive Dengue Virus Neutralizing Antibody that Recognizes a Cryptic Epitope.
    Li J; Watterson D; Chang CW; Che XY; Li XQ; Ericsson DJ; Qiu LW; Cai JP; Chen J; Fry SR; Cheung STM; Cooper MA; Young PR; Kobe B
    Structure; 2018 Jan; 26(1):51-59.e4. PubMed ID: 29249606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eliciting cross-neutralizing antibodies in mice challenged with a dengue virus envelope domain III expressed in Escherichia coli.
    Yang J; Zhang J; Chen W; Hu Z; Zhu J; Fang X; Yuan W; Li M; Hu X; Tan Y; Hu F; Rao X
    Can J Microbiol; 2012 Apr; 58(4):369-80. PubMed ID: 22420529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combinatorial Resurfacing of Dengue Envelope Protein Domain III Antigens Selectively Ablates Epitopes Associated with Serotype-Specific or Infection-Enhancing Antibody Responses.
    Remmel JL; Beauchemin KS; Mishra AK; Frei JC; Lai JR; Bailey-Kellogg C; Ackerman ME
    ACS Comb Sci; 2020 Sep; 22(9):446-456. PubMed ID: 32574486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting of envelope domain III protein of DENV type 2 to DEC-205 receptor elicits neutralizing antibodies in mice.
    Coconi-Linares N; Ortega-Dávila E; López-González M; García-Machorro J; García-Cordero J; Steinman RM; Cedillo-Barrón L; Gómez-Lim MA
    Vaccine; 2013 May; 31(19):2366-71. PubMed ID: 23499580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein.
    Budigi Y; Ong EZ; Robinson LN; Ong LC; Rowley KJ; Winnett A; Tan HC; Hobbie S; Shriver Z; Babcock GJ; Alonso S; Ooi EE
    PLoS Negl Trop Dis; 2018 Feb; 12(2):e0006209. PubMed ID: 29425203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional properties of DENV EDIII‑reactive antibodies in human DENV‑1‑infected sera and rabbit antiserum to EDIII.
    Chen J; Wen K; Li XQ; Yi HS; Ding XX; Huang YF; Pan YX; Hu DM; Di B; Che XY; Fu N
    Mol Med Rep; 2016 Aug; 14(2):1799-808. PubMed ID: 27357403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 52.